These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11893229)

  • 1. Drugs affecting homocysteine metabolism: impact on cardiovascular risk.
    Desouza C; Keebler M; McNamara DB; Fonseca V
    Drugs; 2002; 62(4):605-16. PubMed ID: 11893229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
    Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism.
    De Caterina R; Zampolli A; Madonna R; Fioretti P; Vanuzzo D
    Ital Heart J; 2004 Jun; 5 Suppl 6():19S-24S. PubMed ID: 15185912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.
    Dierkes J; Luley C; Westphal S
    Vasc Health Risk Manag; 2007; 3(1):99-108. PubMed ID: 17583180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate and homocysteine.
    Young IS; Woodside JV
    Curr Opin Clin Nutr Metab Care; 2000 Nov; 3(6):427-32. PubMed ID: 11085827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of genes encoding homocysteine metabolism-related enzymes and risk for cardiovascular disease.
    Malinowska A; Chmurzynska A
    Nutr Res; 2009 Oct; 29(10):685-95. PubMed ID: 19917447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Homocysteine. The cardiovascular risk factor of the next millennium?].
    Suárez García I; Gómez Cerezo JF; Ríos Blanco JJ; Barbado Hernández FJ; Vázquez Rodríguez JJ
    An Med Interna; 2001 Apr; 18(4):211-7. PubMed ID: 11496543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional aspects and possible pathological mechanisms of hyperhomocysteinaemia: an independent risk factor for vascular disease.
    McKinley MC
    Proc Nutr Soc; 2000 May; 59(2):221-37. PubMed ID: 10946791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12].
    Alemán G; Tovar AR; Torres N
    Rev Invest Clin; 2001; 53(2):141-51. PubMed ID: 11421110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine-lowering treatment: an overview.
    van Guldener C; Stehouwer CD
    Expert Opin Pharmacother; 2001 Sep; 2(9):1449-60. PubMed ID: 11585023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans.
    Olthof MR; van Vliet T; Verhoef P; Zock PL; Katan MB
    PLoS Med; 2005 May; 2(5):e135. PubMed ID: 15916468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homocysteine plasma levels in patients treated with antiepileptic drugs depend on folate and vitamin B12 serum levels, but not on genetic variants of homocysteine metabolism.
    Semmler A; Moskau-Hartmann S; Stoffel-Wagner B; Elger C; Linnebank M
    Clin Chem Lab Med; 2013 Mar; 51(3):665-9. PubMed ID: 23382314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperhomocysteinemia--a risk factor for development of occlusive vascular diseases].
    Milosević-Tosić M; Borota J
    Med Pregl; 2002; 55(9-10):385-91. PubMed ID: 12584890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C-->T mutation of the methylenetetrahydrofolate reductase gene.
    Vilaseca MA; Monrós E; Artuch R; Colomé C; Farré C; Valls C; Cardo E; Pineda M
    Eur J Paediatr Neurol; 2000; 4(6):269-77. PubMed ID: 11277368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R; Armitage J
    Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperhomocysteinemia in pediatric age and nutritional aspects of folates: an early cardiovascular risk factor].
    Caramia G; Belardinelli R
    Monaldi Arch Chest Dis; 2006 Dec; 66(4):275-85. PubMed ID: 17312847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine and cardiovascular disease: a review of the evidence.
    Wierzbicki AS
    Diab Vasc Dis Res; 2007 Jun; 4(2):143-50. PubMed ID: 17654449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperhomocysteinemia and cardiovascular disease in animal model.
    Azad MAK; Huang P; Liu G; Ren W; Teklebrh T; Yan W; Zhou X; Yin Y
    Amino Acids; 2018 Jan; 50(1):3-9. PubMed ID: 29018979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.